In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing

Seidlitz, Anne

doi:10.1111/j.2042-7158.2011.01439.x

Cited by 34 publications

(10 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to further illustrate the mechanism of drug release of Ac-Dex particles, we fitted the CUR release data to several commonly utilized drug release models, including: (1) a first order model and (2) Hixson–Crowell model for drug dissolution-controlled release, (3) Higuchi model modified to fit burst release at time 0, (4) Korsmeyer–Peppas model and (5) Baker–Lonsdale for drug diffusion-controlled release, (6) Hopfenberg model for surface erosion-controlled release, (7) Baker’s model for both degradation and diffusion-controlled release, and (8) Weibull model as a general empirical equation to describe a dissolution or release process (Bohrey et al, 2016; Costa and Sousa Lobo, 2001; Kamaly et al, 2016; Seidlitz and Weitschies, 2012; Shuwisitkul, 2011). The coefficient of determinations (R 2 ) of the fit for the models are summarized in Table S3.…”

Section: Resultsmentioning

confidence: 99%

Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery

Wang

Gupta

Meenach

2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Biocompatible, biodegradable polymers are commonly used as excipients to improve the drug delivery properties of aerosol formulations, in which acetalated dextran (Ac-Dex) exhibits promising potential as a polymer in various therapeutic applications. Despite this promise, there is no comprehensive study on the use of Ac-Dex as an excipient for dry powder aerosol formulations. In this study, we developed and characterized pulmonary drug delivery aerosol microparticle systems based on spray-dried Ac-Dex with capabilities of (1) delivering therapeutics to the deep lung, (2) targeting the particles to a desired location within the lungs, and (3) releasing the therapeutics in a controlled fashion. Two types of Ac-Dex, with either rapid or slow degradation rates, were synthesized. Nanocomposite microparticle (nCmP) and microparticle (MP) systems were successfully formulated using both kinds of Ac-Dex as excipients and curcumin as a model drug. The resulting MP were collapsed spheres approximately 1 µm in diameter, while the nCmP were similar in size with wrinkled surfaces, and these systems dissociated into 200 nm nanoparticles upon reconstitution in water. The drug release rates of the Ac-Dex particles were tuned by modifying the particle size and ratio of fast to slow degrading Ac-Dex. The pH of the environment was also a significant factor that influenced the drug release rate. All nCmP and MP systems exhibited desirable aerodynamic diameters that are suitable for deep lung delivery (e.g. below 5 µm). Overall, the engineered Ac-Dex aerosol particle systems have the potential to provide targeted and effective delivery of therapeutics into the deep lung.

show abstract

Section: Resultsmentioning

confidence: 99%

Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery

Wang

Gupta

Meenach

2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The in‐vitro release of ML was studied using the dialysis method [28–30]. Dialysis bags with molecular weight cut‐off of 50 kD were referred to retain the thermosensitive hydrogels, both with and without GP, allowing the release of ML to permeate into the release medium (PBS, pH 7.4).…”

Section: Methodsmentioning

confidence: 99%

Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate

Alexander

AJAZUDDIN²,

Khan

et al. 2014

J Pharm Pharmacol

View full text Add to dashboard Cite

show abstract

“…The method needs to reflect the transport forces that are predominant in vivo (23). This has been demonstrated in methods using a blood vessel-simulating flow-through cell apparatus (24).…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

In Vitro Release Test Methods for Drug Formulations for Parenteral Applications

Gray¹,

Cady²,

Curran³

et al. 2018

Dissolution Technol.

View full text Add to dashboard Cite

In vitro drug release testing for parenteral drug formulations could benefit from more regulatory guidance and compendial information as this testing is a part of current expectations for drug product approval. This Stimuli article discusses in vitro drug release methods for those parenteral drug formulations that are not solutions and explores the challenges involved in using these methods for each formulation type.

show abstract

In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing

Cited by 34 publications

References 109 publications

Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery

Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery

Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate

In Vitro Release Test Methods for Drug Formulations for Parenteral Applications

Contact Info

Product

Resources

About